Comparative Effectiveness of Lithium‐ Vs. Valproate‐Based Combinations With Atypical Antipsychotics in Preventing Rehospitalization After a First Manic Episode of Bipolar I Disorder
- 21 September 2026
- journal article
- research article
- Published by Wiley in Bipolar Disorders
- Vol. 28 (7) , e70184
Abstract
Background: Relapse after a first manic episode is common in bipolar I disorder and frequently leads to rehospitalization. Lithium and valproate, often prescribed with atypical antipsychotics, remain central to maintenance therapy; however, no randomized trials have directly compared these regimens in early‐course illness. This study compared lithium plus atypical antipsychotics (Li + AAPs) versus valproate plus atypical antipsychotics (Val + AAPs) for preventing bipolar‐related rehospitalizations after the first hospitalization for mania. Methods: This was a new‐user, propensity score–matched cohort study of patients discharged after their first hospitalization for acute mania, using Taiwan's National Health Insurance claims data (2011–2022). Patients initiating Li + AAPs or Val + AAPs within 30 days of discharge were followed for rehospitalization for any mood episode (manic, depressive, or mixed). Secondary outcomes included episode‐specific rehospitalization and annualized hospitalization rates. Results: Among 3,909 matched patients (1397 Li + AAP and 2,512 Val + AAP; mean [SD] age, 42.4 [14.2] years; 42.9% male), Li + AAPs were associated with a higher risk of rehospitalization for any mood episode compared to Val + AAPs (hazard ratio [HR], 1.18; 95% CI, 1.03–1.35), primarily driven by manic relapse (HR, 1.16; 95% CI, 1.01–1.35). No significant differences were observed for depressive or mixed episodes. The annual rehospitalization rate for any mood episodes was also higher with Li + AAPs (incidence rate ratio, 1.34; 95% CI, 1.17–1.54). Conclusions: In this nationwide cohort of patients with first‐episode mania, Val + AAPs were associated with a lower risk of bipolar rehospitalization compared to Li + AAPs, suggesting potential early‐phase maintenance advantages of valproate combinations over lithium combinations following first mania discharge.Keywords
Funding Information
- Taipei Veterans General Hospital (V113C‐213)
- Taipei Veterans General Hospital (VGH‐V114C‐146)
- National Science and Technology Council (113‐2314‐B‐075‐039‐MY3)
- National Science and Technology Council (112‐2314‐B‐075‐012)
This publication has 30 references indexed in Scilit:
- Taiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 updateAsian Journal of Psychiatry, 2023
- Monotherapy vs. combination therapy for post mania maintenance treatment: A population based cohort studyEuropean Neuropsychopharmacology, 2019
- Practical recommendations for reportingFine‐Gray model analyses for competing risk dataStatistics in Medicine, 2017
- Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinationsJournal of Affective Disorders, 2017
- Lithium and suicide prevention in bipolar disorderL'Encéphale, 2016
- Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorderCochrane Database of Systematic Reviews, 2013
- MAINTENANCE TREATMENT WITH QUETIAPINE WHEN COMBINED WITH EITHER LITHIUM OR DIVALPROEX IN BIPOLAR I DISORDER: ANALYSIS OF TWO LARGE RANDOMIZED, PLACEBO-CONTROLLED TRIALSDepression and Anxiety, 2013
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- The acute and chronic effects of combined antipsychotic–mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genesProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
- Efficacy of Divalproex vs Lithium and Placebo in the Treatment of ManiaJAMA, 1994